INO-4212: Phase I ongoing

Inovio said it will expand an open-label, U.S. Phase I trial of INO-4212 given either intradermally or intramuscularly followed by electroporation to include an additional 125 healthy volunteers. The company based its decision on data from the first 75 subjects, which showed INO-4212 was well tolerated and showed a strong antibody response to the Ebola glycoprotein antigen following the 3-dose immunization regimen (see BioCentury, April 4). The expanded study will evaluate immune responses generated with fewer intradermal doses, with lower doses and with or without INO-9012, a DNA-based IL-12 immune activator. ...